Go to content Go to menu Go to search

Bio 2011: Lyonbiopôle and 18 Rhône-Alpes companies in Washington DC

27 June 2011

  • version française

On the occasion of the most important international convention in life sciences  "BIO USA", Washington DC, June from 27th to 30th, 2011, Lyonbiopole gathers 18 SMBs from Lyon and Grenoble in the framework of the collective action, co-funded by the Rhône-Alpes Region, Greater Lyon, Grenoble Alpes Metropole and Aderly. Coordinated by Lyon Chamber of Commerce and Industry, in partnership with UbiFrance, the life sciences players of the Rhône-Alpes region are on the 70 sq.m Lyonbiopole's booth under the French pavilion.

Lyonbiopole's highlights during BIO USA 2011

Leaning on its expertise in biotechnologies and vaccines fields, Lyonbiopole is at the initiative of 2 major events in BIO USA 2011.

Monday, June 27th, 2011, from 12:00 am to 5:00 pm: 5th edition of "FastHTrack R&D Partnering with France"

This network event gathers more than 200 international companies and offers the opportunity to  develop R&D collaborations. This collective action of French health-biotech competitiveness clusters is led by Lyonbiopole and is supported by the DGCIS in the framework of their contract with UbiFrance.

This 5th edition will focus on scientific and technological offers of  biotechs and  pharmaceutical  industries'needs, among which Sanofi-Pasteur, Abbott, Boehringer-Ingelheim, AstraZeneca, Eli Lilly and Company, Merck & Co and Ipsen will express themselves. Alizé Pharma and Flamel Technology, based in Lyon, will present their partnership offers.

Wednesday, June 29th, 2011, from 4:00 pm to 4:45 pm: "International Case Studies"

Presentations of:

  • Christian Bréchot, Vice-President in charge of scientific and medical Affairs, and Philippe Cleuziat, Innovation  Programs Director, both coming from the Mérieux Institute 
  • Emanuelle  Trannoy, associate VP, Technologies and European Initiatives, Sanofi-Pasteur
  • Jean-Yves Bonnefoy, VP Research and Development, Transgene

on "Vaccine innovation: a collaborative approach from diagnosis to prevention to treatment".

The Rhône-Alpes region, a territory with no equivalent concerning research and development in life sciences sector

The Rhône-Alpes region is a territory with no equivalent concerning research and development in life sciences sector. Ranked at the 4th position in Europe regarding the number of researchers and on 2nd position of French regions for its private and public research potential, the Rhône-Alpes region differs from other regions thanks to the wealth and the diversity of its economic network.

An ambitious Technological Research Institute, "LyonBioTech", for a comprehensive and personalized management of infectious diseases

To set up and support the health industries on the territory, Lyonbiopole, jointly with the Institut Pasteur, just obtained a Technological Research Institute (TRI) "LyonBioTech", specialized in infectious diseases, within the framework of "Investments for the future" program.

It aims anchoring health industries in the region and fostering the emergence of medium sized companies in promising sector of the future, while responding to public health challenges related to infectious diseases (14 million deaths/year caused by infectious diseases).

LyonBioTech may be considered as a magnet for expertise, a forum for the pooling of skills and a new platform for resources. LyonBioTech comes today within the scope of a foundation for scientific cooperation and research, established from public and private funds and bringing together renowned founders:

  • 2 co-leaders: Lyonbiopole and Institut Pasteur
  • 3 major industrial companies: Sanofi, Mérieux Institute and Danone Research
  • 3 research institutes: INSERM, CNRS, CEA
  • 1 non profit organization of over 50 SMBs from Rhône Alpes and Paris regions

Within 10 years, LyonBioTech has an objective to create 10,000 direct and indirect jobs, in order to reach a critical mass and an international visibility. The budget of LyonBioTech is estimated at more than €700M over a period of 9 years.

About 54.000 sq. ft /5.000 sq. m of real estate dedicated to LyonBioTech
should be available soon at the sites of Lyon Gerland and Institut Pasteur in Paris (at the end, out of a total of 30.000 to 40.000 sq. m/up to 400.000 sq. ft will be available).

Now in a launch phase, LyonBioTech founding members are working with public/private players and partners of the Rhône-Alpes and Paris Regions to elaborate the Institute's legal conditions, set up its leadership and launch the first project.